Managed Healthcare Executive11h
PrEP Overview in Light of Lenacapavir Licensing Agreements
Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...
BMJ10h
Lenacapavir: a giant step forward in HIV prevention—but a missed opportunity for achieving equity and access
This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North ...
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...
GlobalData on MSN11d
Gilead signs agreements to facilitate access to HIV prevention drug
Gilead Sciences has announced the signing of voluntary licencing agreements with six generic pharmaceutical manufacturers to ...
Gilead strikes deal to rush HIV prevention drug to countries most in need
Why Gilead cut a deal with 6 generics companies around a yet-to-be-approved, twice-a-year HIV PrEP drug: "It really is all ...
FiercePharma12d
Gilead strikes licensing deals with 6 generics makers to boost access to long-acting HIV PrEP med
Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...
STAT12d
Gilead strikes voluntary licensing deals in poor countries for its pricey HIV drug
Gilead will license the HIV drug lenacapavir, a twice-yearly injectable, to six generic makers for 120 countries.
Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation
Discover why Gilead Sciences is a strong buy with potential blockbuster drugs in HIV and oncology, favorable valuation, and a ...
Managed Healthcare Executive10d
Gilead to Distribute Lenacapavir in Top HIV Countries, Critics Unhappy
The twice yearly lenacapavir injection will be available in 120 countries with a series of regulatory filings beginning by ...
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell ...
Gilead's tie up with generic cos may not address HIV challenge
Gilead's partnership with generic manufacturers to lower the cost of its HIV drug lenacapavir is criticized for being too ...